A comprehensive review of the peer-reviewed scientific literature finds that MDMA and psilocybin are the 2 schedule I controlled substances with a growing body of evidence supporting their efficacy and safety as medication adjuncts to facilitate manualized psychotherapy for specific disorders (PTSD for MDMA and treatment resistant major depressive disorder and end of life related anxiety and depressive symptoms for psilocybin).
Read the rest here: https://le.utah.gov/interim/2022/pdf/00004231.pdf